75984 Federal Register / Vol. 69, No. 243 / Monday, December 20, 2004 / Notices 

Archives and Records Administration at 

the following Internet address: http://

www.access.gpo.gov/nara/cfr/cfr-tablesearch.html.

The following additional 

requirements apply to this project: 

• AR–7 Executive Order 12372. 

• AR–9 Paperwork Reduction Act 

Requirements. 

• AR–10 Smoke-Free Workplace 

Requirements. 

• AR–11 Healthy People 2010. 

• AR–12 Lobbying Restrictions. 

Additional information on these 

requirements can be found on the CDC 

web site at the following Internet 

address: http://www.cdc.gov/od/pgo/

funding/ARs.htm.

VI.3. Reporting Requirements 

You must provide CDC with an 

original, plus two hard copies of the 

following reports: 

1. Interim progress report, no less 

than 90 days before the end of the 

budget period. Report must contain the 

following elements: 

a. Current Budget Period Activities 

Objectives. 

b. Current Budget Period Financial 

Progress.

c. Additional Requested Information. 

d. Measures of Effectiveness. 

2. Final financial and performance 

reports, no more than 90 days after the 

end of the project period. 

These reports must be mailed to the 

Grants Management or Contract 

Specialist listed in the ‘‘Agency 

Contacts’’ section of this announcement. 

VII. Agency Contacts 

For general questions about this 

announcement, contact: Technical 

Information Management Section, CDC 

Procurement and Grants Office, 2920 

Brandywine Road, Atlanta, GA 30341, 

Telephone: 770–488–2700. 

For program technical assistance, 

contact: Dan Sadler, Project Officer, 

CDC National Center for Chronic 

Disease Prevention, 4770 Buford 

Highway, NE MS K–24, Atlanta, GA 

30341, Telephone: 770–488–6002, Email:DSadler@CDC.gov.

For financial, grants management, or 

budget assistance, contact: Carlos 

Smiley, Grants Management Specialist, 

CDC Procurement and Grants Office, 

2920 Brandywine Road, Atlanta, GA 

30341, Telephone: 770–488–2754, Email: CSmiley@cdc.gov.

VIII. Other Information 

None.

Dated: December 13, 2004. 

William P. Nichols, 

Director, Procurement and Grants Office, 

Centers for Disease Control and Prevention.

[FR Doc. 04–27707 Filed 12–17–04; 8:45 am] 

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Mallinckrodt Chemical Company, 

Destrehan Street Plant

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Department of Health and 

Human Services gives notice of a 

decision to evaluate a petition 

submitted on behalf of a class of 

employees at the Mallinckrodt Chemical 

Company, Destrehan Street Plant, in 

Saint Louis, Missouri to determine 

whether all or some part of the class 

should be included in the Special 

Exposure Cohort under the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000. The 

initial proposed definition for the class 

being evaluated, subject to revision as 

warranted by the evaluation, is as 

follows: 

Facility: Mallinckrodt Chemical 

Company, Destrehan Street Plant, Saint 

Louis, Missouri. 

Locations: All locations in the 

Destrehan Street Plant. 

Job Titles and/or Job Duties: All 

employees that conducted Atomic 

Energy Commission (AEC) work at the 

Destrehan Street Plant. 

Period of Employment: 1942–1957.

FOR FURTHER INFORMATION CONTACT:

Larry Elliott, Director, Office of 

Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health, 4676 Columbia 

Parkway, MS C–46, Cincinnati, OH 

45226, Telephone 513–533–6800 (this is 

not a toll-free number). Information 

requests can also be submitted by e-mail 

to OCAS@CDC.GOV.

Dated: December 13, 2004. 

James D. Seligman, 

Associate Director for Program Services, 

Centers for Disease Control and Prevention.

[FR Doc. 04–27812 Filed 12–17–04; 8:45 am] 

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare and Medicaid 

Services 

[Document Identifier: CMS–R–238] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request

AGENCY: Centers for Medicare and 

Medicaid Services, HHS. 

In compliance with the requirement 

of section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Centers for Medicare and Medicaid 

Services (CMS) (formerly known as the 

Health Care Financing Administration 

(HCFA)), Department of Health and 

Human Services, is publishing the 

following summary of proposed 

collections for public comment. 

Interested persons are invited to send 

comments regarding this burden 

estimate or any other aspect of this 

collection of information, including any 

of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: Inpatient 

Psychiatric Services for Individuals 

Under Age 21 and Supporting 

Regulations in 42 CFR Section 441.151 

and 441.152; Use: Certification 

requirements in 42 CFR 441.151 and 

441.152 require that if it is determined 

that psychiatric services in an inpatient 

setting for individuals under age 21 are 

necessary, certification must be in 

writing before an individual is admitted 

for treatment. This information is used 

by States to document that effective 

screening measures are in place to 

justify the use of inpatient psychiatric 

services; Form Number: CMS–R–238 

(OMB#: 0938–0754); Frequency:

Recordkeeping; Affected Public: State, 

Local or Tribal Govt., Business or other 

for-profit, and Not-for-profit 

institutions; Number of Respondents:

80,000; Total Annual Responses:

80,000; Total Annual Hours: 1. 

To obtain copies of the supporting 

statement and any related forms for the 

proposed paperwork collections 

referenced above, access CMS’s Web site 

Federal Register / Vol. 69, No. 243 / Monday, December 20, 2004 / Notices 75985

address at http://www.cms.hhs.gov/

regulations/pra/, or e-mail your request, 

including your address, phone number, 

OMB number, and CMS document 

identifier, to Paperwork@cms.hhs.gov, 

or call the Reports Clearance Office on 

(410) 786–1326. 

Written comments and 

recommendations for the proposed 

information collections must be mailed 

within 60 days of this notice directly to 

the CMS Paperwork Reduction Act 

Reports Clearance Officer designated at 

the address below: 

CMS, Office of Strategic Operations 

and Regulatory Affairs, Division of 

Regulations Development, Attention: 

Melissa Musotto, Room C5–14–03, 7500 

Security Boulevard, Baltimore, 

Maryland 21244–1850.

Dated: December 8, 2004. 

John P. Burke, III, 

CMS Paperwork Reduction Act Reports 

Clearance Officer, Office of Strategic 

Operations and Regulatory Affairs 

Regulations Development Group.

[FR Doc. 04–27705 Filed 12–17–04; 8:45 am] 

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Tentative 

Schedule of Meetings for 2005

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug 

Administration (FDA) is announcing a 

tentative schedule of forthcoming 

meetings of its public advisory 

committees for 2005. During 1991, at the 

request of the Commissioner of Food 

and Drugs (the Commissioner), the 

Institute of Medicine (the IOM) 

conducted a study of the use of FDA’s 

advisory committees. In its final report, 

one of the IOM’s recommendations was 

for the agency to publish an annual 

tentative schedule of its meetings in the 

Federal Register. This publication 

implements the IOM’s recommendation.

FOR FURTHER INFORMATION CONTACT:

Theresa L. Green, Advisory Committee 

Oversight and Management Staff (HF–

4), Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20857, 

301–827–1220.

SUPPLEMENTARY INFORMATION: The IOM, 

at the request of the Commissioner, 

undertook a study of the use of FDA’s 

advisory committees. In its final report 

in 1992, one of the IOM’s 

recommendations was for FDA to adopt 

a policy of publishing an advance yearly 

schedule of its upcoming public 

advisory committee meetings in the 

Federal Register; FDA has implemented 

this recommendation. The annual 

publication of tentatively scheduled 

advisory committee meetings will 

provide both advisory committee 

members and the public with the 

opportunity, in advance, to schedule 

attendance at FDA’s upcoming advisory 

committee meetings. Because the 

schedule is tentative, amendments to 

this notice will not be published in the 

Federal Register. However, changes to 

the schedule will be posted on the FDA 

advisory committees’ Internet site 

located at http://www.fda.gov/oc/

advisory/default.htm. FDA will 

continue to publish a Federal Register

notice 15 days in advance of each 

upcoming advisory committee meeting, 

to announce the meeting (21 CFR 14.20).

The following list announces FDA’s 

tentatively scheduled advisory 

committee meetings for 2005. You may 

also obtain up-to-date meeting 

information by calling the Advisory 

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the 

Washington, DC area).

Committee Name Tentative Date(s) of Meetings 

Advisory Committee 10–

Digit Information Line 

Code 

OFFICE OF THE COMMISSIONER

Pediatric Advisory Committee February 14–15, June-day to be announced, November-day to be announced8732310001

Science Board to the Food and Drug Administration April 15, November-day to be announced 3014512603

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

Allergenic Products Advisory Committee April 7 3014512388

Cellular, Tissue and Gene Therapies Advisory Committee 

(formerly Biological Response Modifiers Advisory Committee)

March 3–4, July 28–29, November 9–10 3014512389

Blood Products Advisory Committee March 17–18, July 21–22, December 1–2 3014519516

Transmissible Spongiform Encephalopathies Advisory 

Committee

February 8–9, June 28–29, October 27–28 3014512392

Vaccines and Related Biological Products Advisory CommitteeFebruary 16–17, March 15–16, May 4–5, September 

20–21, November 16–17

3014512391

CENTER FOR DRUG EVALUATION AND RESEARCH

Anesthetic and Life Support Drugs Advisory Committee May 24–25, July 20–21, November 9–10 3014512529

Anti-Infective Drugs Advisory Committee To Be Announced 3014512530

Antiviral Drugs Advisory Committee March 10–11, August 3–4 3014512531

Arthritis Advisory Committee February 16–17, May 12–13, September 15–16 3014512532